| Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy PM George, AU Wells, RG Jenkins The Lancet Respiratory Medicine 8 (8), 807-815, 2020 | 1144 | 2020 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, HJC McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 594 | 2021 |
| Respiratory follow-up of patients with COVID-19 pneumonia PM George, SL Barratt, R Condliffe, SR Desai, A Devaraj, I Forrest, ... Thorax 75 (11), 1009-1016, 2020 | 466 | 2020 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 381 | 2022 |
| Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities PM George, P Spagnolo, M Kreuter, G Altinisik, M Bonifazi, FJ Martinez, ... The lancet Respiratory medicine 8 (9), 925-934, 2020 | 304 | 2020 |
| The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements AM Hoffmann-Vold, TM Maher, EE Philpot, A Ashrafzadeh, R Barake, ... The Lancet Rheumatology 2 (2), e71-e83, 2020 | 296 | 2020 |
| Lung transplantation for idiopathic pulmonary fibrosis PM George, CM Patterson, AK Reed, M Thillai The Lancet Respiratory Medicine 7 (3), 271-282, 2019 | 252 | 2019 |
| Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study TM Drake, AB Docherty, EM Harrison, JK Quint, H Adamali, S Agnew, ... American journal of respiratory and critical care medicine 202 (12), 1656-1665, 2020 | 240 | 2020 |
| Pharmacology and therapeutic potential of interferons PM George, R Badiger, W Alazawi, GR Foster, JA Mitchell Pharmacology & therapeutics 135 (1), 44-53, 2012 | 212 | 2012 |
| Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial D Visca, L Mori, V Tsipouri, S Fleming, A Firouzi, M Bonini, MJ Pavitt, ... The Lancet Respiratory Medicine 6 (10), 759-770, 2018 | 210 | 2018 |
| Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007 PM George, W Banya, N Pareek, D Bilton, P Cullinan, ME Hodson, ... Bmj 342, 2011 | 193 | 2011 |
| Evidence for the involvement of type I interferon in pulmonary arterial hypertension PM George, E Oliver, P Dorfmuller, OD Dubois, DM Reed, NS Kirkby, ... Circulation research 114 (4), 677-688, 2014 | 154 | 2014 |
| Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post–COVID-19 study I Stewart, J Jacob, PM George, PL Molyneaux, JC Porter, RJ Allen, ... American journal of respiratory and critical care medicine 207 (6), 693-703, 2023 | 105 | 2023 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 92 | 2023 |
| A persistent neutrophil-associated immune signature characterizes post–COVID-19 pulmonary sequelae PM George, A Reed, SR Desai, A Devaraj, TS Faiez, S Laverty, A Kanwal, ... Science translational medicine 14 (671), eabo5795, 2022 | 77 | 2022 |
| Performance of Xpert MTB/RIF in the diagnosis of tuberculous mediastinal lymphadenopathy by endobronchial ultrasound DJ Dhasmana, C Ross, CJ Bradley, DW Connell, PM George, ... Annals of the American Thoracic Society 11 (3), 392-396, 2014 | 69 | 2014 |
| A comparison between two strategies for monitoring hepatic function during antituberculous therapy A Singanayagam, S Sridhar, J Dhariwal, D Abdel-Aziz, K Munro, ... American journal of respiratory and critical care medicine 185 (6), 653-659, 2012 | 69 | 2012 |
| The respiratory microbiome in chronic hypersensitivity pneumonitis is distinct from that of idiopathic pulmonary fibrosis R Invernizzi, BG Wu, J Barnett, P Ghai, S Kingston, RJ Hewitt, J Feary, ... American journal of respiratory and critical care medicine 203 (3), 339-347, 2021 | 64 | 2021 |
| Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID) JM Wild, JC Porter, PL Molyneaux, PM George, I Stewart, RJ Allen, R Aul, ... BMJ Open Respiratory Research 8 (1), 2021 | 58 | 2021 |
| King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference CM Nolan, SS Birring, M Maddocks, TM Maher, S Patel, RE Barker, ... European Respiratory Journal 54 (3), 2019 | 58 | 2019 |
Athol U WellsProfessor of Respiratory Medicine, Imperial College,Correu electrònic verificat a rbht.nhs.uk
